| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7459561 | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Oct, 2020
(3 years ago) | |
| US6812238 | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Oct, 2025
(1 year, 6 months from now) | |
| US10812238 | ASTELLAS | Configurable reference signals |
Oct, 2025
(1 year, 6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6812238 (Pediatric) | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
May, 2026
(2 years from now) | |
| US10603280 | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Sep, 2027
(3 years from now) | |
| US10206879 | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Sep, 2027
(3 years from now) | |
|
US10603280 (Pediatric) | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Mar, 2028
(3 years from now) | |
|
US10206879 (Pediatric) | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Mar, 2028
(3 years from now) | |
Cresemba is owned by Astellas.
Cresemba contains Isavuconazonium Sulfate.
Cresemba has a total of 8 drug patents out of which 1 drug patent has expired.
Expired drug patents of Cresemba are:
- US7459561
Cresemba was authorised for market use on 22 November, 2022.
Cresemba is available in capsule;oral, powder;intravenous dosage forms.
Drug patent challenges can be filed against Cresemba from 08 June, 2030.
The generics of Cresemba are possible to be released after 08 June, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-90) | Mar 06, 2022 |
| New Chemical Entity Exclusivity(NCE) | Mar 06, 2020 |
| Orphan Drug Exclusivity(ODE-305) | Mar 06, 2022 |
| Orphan Drug Exclusivity(ODE-458) | Dec 08, 2030 |
| New Patient Population(NPP) | Dec 08, 2026 |
| Orphan Drug Exclusivity(ODE-454) | Dec 08, 2030 |
| ODE*(ODE*) | Mar 06, 2022 |
| Pediatric Exclusivity(PED) | Jun 08, 2031 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 06, 2027 |
| Orphan Drug Exclusivity(ODE) | Mar 06, 2022 |
Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient
NCE-1 date: 08 June, 2030
Market Authorisation Date: 22 November, 2022
Treatment: NA
Dosage: CAPSULE;ORAL; POWDER;INTRAVENOUS
CRESEMBA family patents
